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PRACTICAL IMPLICATIONS OF NANODOSIMETRY IN MEDICINE
Jahangir A. Satti  Albany Medical College
 The grandiose promises made decades ago of cost reduction, miracle cures for cancers
and universal availability of nanomedicine are still a far cry. Even we do not have any viable
model to exploit nanotechnology in medicine. The most important arena of the nan-
otechnology is the development of nanoscale drugs for routine clinical practice. The cur-
rent chemo protocols are based on maximum tolerable dose philosophy. Such a dose,
when translated into active nanoscale clusters, quantitatively outnumbers the cells in an
average human body. These nanoscale drug issues are discussed in this paper. A theoreti-
cal framework for commonly used drug aspirin has been considered as an example. The
possible quantum physical effects have also been theoretically evaluated. Further, the
amount of drug molecules in a standardized aspirin dose of 100 milligram has been com-
puted into nanoclusters. The calculations show that the processing of nanoscale drug is a
monumental task which requires new types of manufacturing facilities. Also there is a need
to develop new protocols which will help realize the practical implementation of nan-
odosimetry in day to day drug administrations. These protocols will need to examine the
implications of dose-responses such as necrosis, apoptosis and hormesis in medicine for
routine clinical practice.
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INTRODUCTION
Nano scale material manipulation is an emerging field of science and
technology. Its prospective impacts in medical industry are extensive. The
expected applications range from surgical sutures to manipulating molec-
ular machinery to treat the complex diseases. There are valid public con-
cerns about severe toxicities associated with nanoparticles especially due
to their translocations in a living system. There are also unknown conse-
quences related to nanoparticles compared to their bulkscale counter-
parts consisting on same materials. However, there are other scientific
and physical challenges related to nanoparticle manufacturing, dispens-
ing and administration to patients in routine clinical practice. We will
limit our discussion to quantum level behaviors, manufacturing issues
and dispensing problems in nanodosimetry.
The United States in Americas, Liberia in Africa and Myanmar in Asia
are the only countries in the world that still use an obsolete system of
measurements in their daily lives. The rest of the world is using standard
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metric units known as MKS system. The MKS system of units is an abbre-
viation of Meter for length, Kilogram for weight and second for time. The
second, as a time unit, is common to all systems. Liberia is too poor to
change and Myanmar is too isolated to have any need or an impact in the
international market. But the sole super power is too rich to afford the
cost to change to standard metric system. Reasoning along the same lines
the question arises: Will our current medical drug industry be ready to
embrace the emerging nano drug manufacturing processes in near
future? The drug manufacturing issue in the United States becomes
extremely important because of its leadership in science and technology
in the world. Unlike metric system, most of the world’s drug industries
and countries follow the USA pharmaceutical models for their healthcare
needs. We need to evaluate the implications of nanotechnology in med-
ical chemodosimetry to answer this question.
Generally it is claimed that everything in this universe is made of
atoms. An atom of an element has neutrons, protons and electrons as its
constituents plus binding energies that hold these ingredients together.
Hydrogen atom is an exception which has only one proton and one elec-
tron. However, the objective of nano-scale technology is to exploit nano-
size properties of materials. The alleged nanoscale is much smaller than
our existing bulkscale material compositions but far larger than single
atom of any element. Nanotechnology is popularly described as a method
to assemble materials in an atom by atom or molecule by molecule fash-
ion. The benefits of nano-scale properties are well documented in the
research journals. In this article we will discuss the implications of nano
technology in medical chemo-dosimetry. A length of 100 nanometer
(nm) has been established as an upper metric to classify nano entities.
One nanometer is one billionth of a meter in length i.e., 10-9. The mate-
rials, in general, assume bulkscale properties beyond this length. (Poole
and Owens 2003).
Historically physicians have adapted Maximum Tolerable Dose
(MTD) therapy protocol to administer drugs to treat infectious diseases
and malignancies. The objective of MTD protocol is to deliver maximum
lethal dose to unwanted pathogens and malignant cells inside the body.
The amount of such a lethal dose depends on many confounding factors
including host’s immunity status, age and the nature of a particular dis-
ease. Drugs are also administered in a cocktail fashion consisting on mul-
tiple prescriptions or in alternation with each other. The prescribed dose
of a drug can range from microgram (μg) to gram (gm) per day for an
individual. For instance the standard Arsenic Trioxide (As2O3) dose
administered in Acute Promyelocytic Leukemia (APL) is about 10 mil-
ligram (mg) per day (Douer 2000). However, the dose of another drug,
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The nanoparticles exhibit different characteristics in physical, chem-
ical and biological domains compared to their bulkscale counterparts.
The quantum uncertainties associated with smaller size particles may
become pronounced at nanoscale. Their optical, vibrational, electrical,
mechanical, rotational, magnetic and biological properties are different
from their bulkscale siblings consisting on the same chemical composi-
tions. The nanoparticle based reactions are amplified manifold because
of their pronounced spread and expanded surface chemistry. For
instance, a given amount of salt in nano formulation produces 10-30
times more chemical reaction than the same amount of salt in bulkscale
form. Nanoparticles also trigger different biological reactions than
bulkscale materials. This is mainly due to the translocation of nanoparti-
cles inside a living system. A nanoparticle is highly vibrant and penetrates
far deeper inside a living cell than aggregated molecules of the same
material. Their biological reactions also change because of their translo-
cations inside the cells. The physical and biological clearance of nanopar-
ticles is yet another area of great concern regarding their side effects.
In this article, we would like to explain the implications of nanotech-
nology with respect to commonly used drug, aspirin, to elaborate its var-
ious aspects. Aspirin is the appropriate candidate for evaluation in terms
of nanoscale implications because of its frequent uses as a common drug
around the world. Aspirin is widely used as a standard drug therapy in the
primary and secondary prevention of cardiovascular diseases (ATT
2009). Low dose aspirin saves cost significantly (Tsutani et al., 2006,
Elwood et al., 1998). Some studies show that doses of 75 mg and 325 mg
are equally effective in the prevention of cardiovascular diseases.
Malhotra et al. (2003) evaluated effects of 50, 80, 100, 162.5 and 325
mg aspirin doses which are widely used in clinical practice. However, they
concluded that doses of aspirin less than 100 mg were not as effective in
inhibiting platelet aggregation as doses greater than 100 mg Aspirin has
been also credited as a promising chemoprevention agent in colorectal
adenomas (Cole et al., 2009, Grau et al., 2009). The doses of aspirin in
these studies ranged from 81 to 325 mg.
Historically, low dose aspirin is defined as 81-160 mg per day and
higher-dose aspirin ranges between 300 – 325 mg per day. In another
study the use of two standard tablets of aspirin consisting on a dose of 650
mg per week had significant reduction in the risk of colorectal cancer
(Chan et al., 2005).
NANOCLUSTERS PER DOSE
An aspirin molecule has a diameter of 1 nm. Its chemical formula is
C9H8O4 and molecular weight is 180. As described earlier the upper limit
defined for nano-scale entities is 100 nm (Poole and Owens 2003). We
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assume for simplicity that a dose consisting on 100 aspirin molecules con-
stitute a single aspirin nanocluster. If the mass of a typical dose, m, is 100
mg then the number of aspirin molecules, N, in such a dose can be cal-
culated by using the formula:
(1)
where NA is Avogadro number, 6.02×10
23, and Aw is the molecular weight
of an aspirin molecule. This assumption ignores all other correction fac-
tors such as effects of temperature, atmospheric pressure, humidity etc.
on aspirin structure. The number of molecules in a 100 mg aspirin dose
will be 3.34×1020. If each aspirin nanocluster contains 100 molecules then
a 100 mg aspirin dose consists on 3.34×1018 nanoclusters. The total length
of clusters can be calculated by
(2)
where d is the diameter of a cluster and n is the total number of clusters
in a dose. The value of n= 0,1,2,3,....No. We assume that each cluster can
be placed at least 50 nm apart from other clusters to avoid aggregation.
This assumption appears realistic due to the physical limits imposed by
our current manufacturing technologies.
MANUFACTURING MOLECULE BY MOLECULE
Suppose if one nanosecond (nsec) is required to act on one molecule
then the time required to act on 3.3×1020 molecules will be 3.3×1011 sec-
onds or 10464.2 years.
Light Days Time: We assume that we have the capability to tackle each
molecule with the speed of light. The total length formed by 100 mg
aspirin molecules will be 3.3×1013 m. If we tackle each molecule with the
speed of light then the total time required to account for all the mole-
cules will be 1.1×105 light sec or 1.27 light days.
Assembling Clusters into a Dose: Suppose the same timeline of 1 nsec is
needed to assemble one nanocluster composed on 100 aspirin molecules
then the total time required to assemble 100 mg aspirin into a nano dose
will be 106 years.
QUANTUM MECHANICAL EFFECTS
Researchers often raised the question if quantum mechanical effects
related to microscopic objects become pronounced at nano levels. Such
effects are mainly due to the pronounced wave-particle duality of matter
in quantum world. A precise positioning mechanism is needed to accu-
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fashion. If we ever develop the technology to handle individual molecule
to be placed at a precise location then what type of uncertainty would be
associated with such positioning mechanism? This can be estimated by
calculating the associated positional probability due to the cluster size.
Furthermore, such calculations are also needed to estimate the probabil-
ity of misplacement of a drug cluster in an intended cell target in a
research setup. These calculations are also needed to estimate the proba-
ble surface area of a drug vehicle. Drug vehicles are used to transport
nanoclusters to a particular target inside the body.
The purpose of this section is to estimate the quantum-wave effects
associated with an aspirin nanocluster. This will also help us determine
how far off a drug nanocluster may land from its intended target due to
its pronounced wave effects. Generally simulation program consisting on
complex mathematical tools on computers are used to calculate these
quantum effects. Such calculations are mainly based on models derived
from Schrödinger wave equation. In this article we will use simple equa-
tions to determine the quantum wave associated with a nanocluster con-
sisting on 100 aspirin molecules. The objective is to evaluate if this issue
is worth exploring further in nanomedicine. To calculate the wavelength
associated with a 100 nm cluster we use the equation:
(3)
where m is the mass of a nanocluster, c is the velocity of light and h is
Plank’s constant.
The density of aspirin is 1.40 g/cm3. We can calculate the mass, m, by
using formula:
(4)
where ρ is the density of aspirin and v is the volume. The volume of 100
nm diameter aspirin nanocluster can be calculated by using the formula:
(5)
Volume = 4/3(π × (5 × 10-6)3 cm3 )= 523.6 × 10-18 cm3.
Mass of an aspirin nanocluster is = density × volume = 1.40 (g/cm3) ×
523.6 × 10-18 cm3 or mass = 733.04 × 10-21 Kg.
Now we can calculate the wavelength associated with an aspirin nan-
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.as by definition J = m2 Kg sec-2.
The wavelength associated with a 100 nm aspirin nanocluster is
extremely smaller than the nucleus of a Hydrogen atom. So the quantum
probability of an aspirin cluster to fall outside of its intended target in a
typical 10 micron living cell is almost zero.
INTERCLUSTER ATTRACTION
Given the mass of 733.04 × 10-21 Kg per nanocluster and inter-cluster
distance of 150 nm, the attractive force between two aspirin nanoclusters
is 159.3 × 10-35 N. Being other factors, such as Van der Wall forces,
ignored these clusters are far apart from each other and will not aggre-
gate to form bulkscale masses.
SURFACE AREA
We would like to estimate the surface area required to spread aspirin
nanoclusters at a distance of 50 nm from each other. Using the formula
Ln=d(2n+1) as defined in equation (2) the total length formed by 100 mg
aspirin nanoclusters is
L3.34x10
18 = 100(2 × 3.34 × 1018+1) = 6.68 × 1020 nm. Area covered by
these clusters will be 2.585 × 1010 nm2 = 25.85 m2.
If all the aspirin clusters are coated on the outer surface of a spheri-
cal shell then the diameter of such a pill will be:
(6)
d = 2.87 m or 287 cm.
If an average height of an individual is 1.8 meter then the pill itself
will be over 1.50 times taller than the average height of the user.
This volume may be reduced by producing pills in different geomet-
rical configurations where nanoclusters can be spread on inner surfaces.
However, this will complicate the manufacturing processes thus leading
to higher prices and compromising the stability of the pill structures.
CELLULAR UPTAKE
In conventional bulkscale dosage extra drug amount is excreted in
aggregate form from the system which pollutes our waterways.
Furthermore, the aggregated drugs in bulkscale forms have limited pen-
etrations inside the living organism due to their larger sizes and body’s
d A=
π
λ = 00 03. pÅ
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resistance to further uptake after initial exposure. However, the scenario
with nanocluster is different: Their damaging effects are mostly unknown
in a living system as well as in the environment. In reality one needs a frac-
tion of the existing MTD dose in nano formulation because of the opti-
mal absorption and expanded chemical reactivity of the particles.
It has been estimated that there are 20 to 30 trillion cells in an aver-
age human body. Suppose we administer a 100 mg dose consisting on
aspirin nanoclusters to an individual. Each nanocluster contains 100
aspirin molecules. The number of nanoculsters in a 100 mg aspirin dose
far exceeds the number of cells in the body if each cell uptakes one nan-
ocluster (i.e., 100 aspirin molecules per cell). If these extra aspirin nan-
oclusters pass through kidneys they can cause irreparable damage to
them. Since there are only one million nephrons in each kidney, just few
doses of nanocluster-based aspirin can completely wipe them out.
As described above, each 100 mg aspirin dose can be developed into
3.34 million trillion (3.34x1018) nanoclusters. If there are 30 trillion cells
in an average human body, then 100 mg aspirin nanoclusters is sufficient
to saturate over 100,000 individuals and their pets. This claim is support-
ed by mathematical calculations as the numbers do not lie.
CHALLENGES TO BE TACKLED
1. How to produce drugs composed on nanoclusters? Such nanoclus-
ters-based drugs need not aggregate into bulkscale formulation over
time.
2. How to assemble nano-drugs efficiently, economically and timely into
manageable dispensing pills or suspensions for routine clinical prac-
tice?
3. How biocompatible vehicles be manufactured to transport nanoclus-
ters for optimal therapeutic effects?
4. How to establish QA benchmarks for all the processes described in 1,
2 and 3.
5. How to achieve precision manufacturing technology at 50 nm scale?
6. Dose-response quantification to evaluate different biological effects
such as necrosis, apoptosis, hormesis, etc. with different doses of
drugs.
7. Studies of known and prospective additional new toxicities associated
with common over the counter as well as prescription drugs due to
their nanoscale effects. Such toxicities need evaluation in both quan-
titative and qualitative domains.
8. Nanodosimetry standardization based on Time-Dose-Response and
Fractionation.
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CONCLUSION
There are already numerous issues associated with MTD protocol.
The foremost issue is the severe side effects produced by MTD with
bulkscale formulations. Such side effects with nanoscale drugs will aggra-
vate manifolds in addition to other unknown complications because of
the translocations of nanoparticles deep inside tissues. There is an emerg-
ing evidence that smaller drug doses produce better results with mini-
mum toxicity in chronic diseases especially in advance cancers (Satti
2009). Chemicals and radiation produce multiphase biological reactions
with different doses. Stronger doses of drugs produce necrosis inside the
host body. However, smaller doses produce hormesis and apoptosis.
Apoptosis is a highly desirable biological process to heal a system without
any significant adverse side effects. Hormesis can induce resistance in a
biological system which can be administered as a prophylactic modality in
preventive medicine. Yet further diluted doses produce bystander effects.
Even a single charged particle can inflict lethal damage to a cell which in
turn can produce bystander deaths in hundreds of other cells ( Gaillard
et al. 2009). We also know that energies less than 1 electron volt (eV) can
produce symmetric, asymmetric and other vibrational effects in mole-
cules (Anderson 1984). For comparison the photon energy from an
incandescence light bulb ranges between 1 - 3 eV. There is an urgent
need to revise our centuries old chemical dosimetery protocol, especially
if we would like to avail the emerging nanotechnology in our daily prac-
tices. It is expected that such changes will come in big savings and better
cure rates for chronic diseases in addition to other rewards such as envi-
ronmental protections and ecological preservations. However to reap
these rewards scientists need to overcome monumental task of nanomed-
icine from manufacturing, drug evaluation, dose specification, toxicolog-
ical studies, clinical trials and QA maintenance in a clinical setup. The
question remains to be seen if the rest of the world will wait for the USA
to show leadership in nanomedicine dosimetry or they will take their own
initiatives and set new standards in this emerging arena?
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